Company intelligence / Profile preview

Hainan Linheng Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Hainan Linheng Pharmaceutical is a high-tech pharmaceutical enterprise focused on the development, production, and sales of pharmaceutical products. The company has GMP-certified manufacturing facilities and leverages advanced clinical and medical research from Beijing and Shanghai to support its R&D activities. It was listed on China's New OTC Market ("new three board") in 2016 under the stock code 835509.

Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Compound Ganmaoling tablet

Unknown

Beyond the preview

Go deeper on Hainan Linheng Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hainan Linheng Pharmaceutical.